Inclusion Body Myositis (IBM)

Overview

Epidemiology

• Prevalence: ~5–70 per million (most common inflammatory myopathy in those >50 years)
• Male predominance (~3:1 male to female ratio)
• Onset typically after age 50; rarely before age 45
• Slowly progressive; most patients require ambulatory aids within 10–15 years

Pathogenesis

• CD8+ cytotoxic T cells invade MHC-I expressing, non-necrotic muscle fibers (same as polymyositis)
• Clonally expanded, antigen-driven T-cell response

• Abnormal protein aggregation within muscle fibers: amyloid precursor protein (APP), phosphorylated tau, TDP-43, p62, ubiquitin
• Formation of rimmed vacuoles and tubulofilamentous inclusions (15–21 nm diameter on electron microscopy)
• Cytochrome oxidase (COX)-negative fibers reflect mitochondrial dysfunction
• Resembles a muscle "proteinopathy" akin to neurodegenerative disease

Clinical Features

Key distinguishing point: asymmetric, distal > proximal weakness with selective finger flexor + quadriceps involvement is virtually pathognomonic for IBM.

Diagnosis

Diagnostic Criteria (2011 ENMC Criteria — key elements)

1. Age >45, duration >12 months
2. Finger flexor or quadriceps weakness
3. Biopsy showing endomysial inflammation + rimmed vacuoles OR p62/TDP-43 inclusions

Laboratory Findings

• CK: Normal or mildly elevated (up to 10× normal; often <1000 U/L — lower than polymyositis)
• Anti-cN-1A antibody (anti-NT5C1A): Present in ~33–70%; not diagnostic alone but supports IBM
• ANA and myositis-specific antibodies (anti-Jo-1, etc.) typically negative

EMG

• Mixed pattern: myopathic + neuropathic features (short-duration and long-duration MUAPs, fibrillations)

MRI

• Selective involvement of quadriceps (especially rectus femoris spared relative to vastus lateralis) and forearm flexors

Muscle Biopsy — Gold Standard

• Rimmed vacuoles lined by granular material (H&E)
• Endomysial inflammation (CD8+ T cells invading non-necrotic fibers)
• COX-negative fibers (mitochondrial dysfunction)
• p62-positive cytoplasmic inclusions
• Tubulofilamentous inclusions (15–21 nm) on electron microscopy

Differential Diagnosis

Management

Pharmacological

• No proven disease-modifying therapy — IBM is largely refractory to immunosuppression
• Corticosteroids: Trials consistently show no sustained benefit; may transiently improve inflammation but not function
• IVIG: May modestly benefit dysphagia in some patients; no effect on limb strength
• Other immunosuppressants (methotrexate, azathioprine, cyclosporine): No proven benefit
• Bimagrumab (anti-ActRII antibody): Showed increased lean mass in trials; ongoing investigation
• Rapamycin (sirolimus): Phase 2 trials exploring the autophagy/mTOR pathway — early results modestly promising

Non-Pharmacological (cornerstone of care)

• Physical therapy: Resistance training and aerobic exercise are safe and may slow functional decline
• Occupational therapy: Adaptive devices for hand function (jar openers, key turners)
• Speech therapy + swallowing evaluation: Critical for dysphagia; PEG tube if severe
• Orthotics: Ankle-foot orthoses (AFOs) for foot drop
• Fall prevention: Home modifications, walking aids

Prognosis

• Slowly but relentlessly progressive — no spontaneous remission
• Most patients lose independent ambulation within 10–15 years of symptom onset
• Dysphagia is a major source of morbidity (aspiration pneumonia)
• Respiratory muscle involvement occurs in advanced disease
• Life expectancy modestly reduced; leading causes of death include aspiration pneumonia and falls

Key Distinguishing Points vs. Other IIMs